Which has preferable earnings and valuation, GMAB or INDV?

Genmab A/S has higher revenue and earnings than Indivior. Genmab A/S is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genmab A/S $3.72B 4.22 $963M $1.32 19.05 Indivior $1.24B 3.70 $210M $1.95 19.29

Is GMAB or INDV more profitable?

Genmab A/S has a net margin of 21.05% compared to Indivior's net margin of 19.44%. Genmab A/S's return on equity of 15.34% beat Indivior's return on equity. Company Net Margins Return on Equity Return on Assets Genmab A/S 21.05% 15.34% 8.94% Indivior 19.44% -219.26% 29.40%

Which has higher valuation and earnings, INDV or ASND?

Indivior has higher revenue and earnings than Ascendis Pharma A/S. Indivior is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Indivior $1.24B 3.70 $210M $1.95 19.29 Ascendis Pharma A/S $814.57M 16.12 -$258M $8.67 24.27

Which has higher valuation and earnings, INDV or BBIO?

Indivior has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Indivior $1.24B 3.70 $210M $1.95 19.29 BridgeBio Pharma $502.08M 26.37 -$724.93M -$3.74 N/A

Do analysts rate INDV or RGC?

Indivior currently has a consensus target price of $39.33, suggesting a potential upside of 4.55%. Given Indivior's stronger consensus rating and higher possible upside, equities analysts plainly believe Indivior is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indivior 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, INDV or RGC?

Indivior has higher revenue and earnings than Regencell Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Indivior $1.24B 3.70 $210M $1.95 19.29 Regencell Bioscience N/A N/A -$3.58M N/A N/A

Indivior (INDV) Competitors

$37.62 +0.17 (+0.45%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$37.90 +0.28 (+0.74%)

As of 06/5/2026 07:37 PM Eastern

Compare

INDV vs. GMAB, ASND, BBIO, SMMT, and RGC

Should you buy Indivior stock or one of its competitors? MarketBeat compares Indivior with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Indivior include Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Summit Therapeutics (SMMT), and Regencell Bioscience (RGC). These companies are all part of the "pharmaceutical products" industry.

How does Indivior compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Indivior (NASDAQ:INDV) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

In the previous week, Genmab A/S had 2 more articles in the media than Indivior. MarketBeat recorded 2 mentions for Genmab A/S and 0 mentions for Indivior. Genmab A/S's average media sentiment score of 0.71 beat Indivior's score of 0.53 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Overall Sentiment
Genmab A/S	Positive
Indivior	Positive

Genmab A/S has a net margin of 21.05% compared to Indivior's net margin of 19.44%. Genmab A/S's return on equity of 15.34% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Indivior	19.44%	-219.26%	29.40%

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 0.7% of Indivior shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Genmab A/S has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, Indivior has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

Genmab A/S presently has a consensus price target of $37.93, suggesting a potential upside of 50.81%. Indivior has a consensus price target of $39.33, suggesting a potential upside of 4.55%. Given Genmab A/S's higher probable upside, equities analysts clearly believe Genmab A/S is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Genmab A/S has higher revenue and earnings than Indivior. Genmab A/S is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.22	$963M	$1.32	19.05
Indivior	$1.24B	3.70	$210M	$1.95	19.29

Summary

Genmab A/S beats Indivior on 10 of the 16 factors compared between the two stocks.

How does Indivior compare to Ascendis Pharma A/S?

Indivior (NASDAQ:INDV) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

Ascendis Pharma A/S has a net margin of 57.87% compared to Indivior's net margin of 19.44%. Ascendis Pharma A/S's return on equity of 0.00% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	19.44%	-219.26%	29.40%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Indivior presently has a consensus target price of $39.33, suggesting a potential upside of 4.55%. Ascendis Pharma A/S has a consensus target price of $295.39, suggesting a potential upside of 40.36%. Given Ascendis Pharma A/S's higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

60.3% of Indivior shares are held by institutional investors. 0.7% of Indivior shares are held by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Indivior has higher revenue and earnings than Ascendis Pharma A/S. Indivior is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.70	$210M	$1.95	19.29
Ascendis Pharma A/S	$814.57M	16.12	-$258M	$8.67	24.27

Indivior has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market.

In the previous week, Ascendis Pharma A/S had 6 more articles in the media than Indivior. MarketBeat recorded 6 mentions for Ascendis Pharma A/S and 0 mentions for Indivior. Ascendis Pharma A/S's average media sentiment score of 1.13 beat Indivior's score of 0.53 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Overall Sentiment
Indivior	Positive
Ascendis Pharma A/S	Positive

Summary

Ascendis Pharma A/S beats Indivior on 11 of the 16 factors compared between the two stocks.

How does Indivior compare to BridgeBio Pharma?

Indivior (NASDAQ:INDV) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

60.3% of Indivior shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 0.7% of Indivior shares are owned by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Indivior has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.70	$210M	$1.95	19.29
BridgeBio Pharma	$502.08M	26.37	-$724.93M	-$3.74	N/A

In the previous week, BridgeBio Pharma had 7 more articles in the media than Indivior. MarketBeat recorded 7 mentions for BridgeBio Pharma and 0 mentions for Indivior. BridgeBio Pharma's average media sentiment score of 0.72 beat Indivior's score of 0.53 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Indivior	Positive
BridgeBio Pharma	Positive

Indivior has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

Indivior has a net margin of 19.44% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	19.44%	-219.26%	29.40%
BridgeBio Pharma	-124.42%	N/A	-65.81%

Indivior presently has a consensus price target of $39.33, indicating a potential upside of 4.55%. BridgeBio Pharma has a consensus price target of $89.59, indicating a potential upside of 32.51%. Given BridgeBio Pharma's higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.85

Summary

BridgeBio Pharma beats Indivior on 9 of the 17 factors compared between the two stocks.

How does Indivior compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Indivior (NASDAQ:INDV) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Summit Therapeutics currently has a consensus price target of $26.05, suggesting a potential upside of 76.40%. Indivior has a consensus price target of $39.33, suggesting a potential upside of 4.55%. Given Summit Therapeutics' higher possible upside, equities analysts clearly believe Summit Therapeutics is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by company insiders. Comparatively, 0.7% of Indivior shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Indivior has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Indivior	$1.24B	3.70	$210M	$1.95	19.29

Summit Therapeutics has a beta of -1.32, indicating that its stock price is 232% less volatile than the broader market. Comparatively, Indivior has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

In the previous week, Summit Therapeutics had 19 more articles in the media than Indivior. MarketBeat recorded 19 mentions for Summit Therapeutics and 0 mentions for Indivior. Indivior's average media sentiment score of 0.53 beat Summit Therapeutics' score of 0.50 indicating that Indivior is being referred to more favorably in the news media.

Company	Overall Sentiment
Summit Therapeutics	Positive
Indivior	Positive

Indivior has a net margin of 19.44% compared to Summit Therapeutics' net margin of 0.00%. Indivior's return on equity of -219.26% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Indivior	19.44%	-219.26%	29.40%

Summary

Indivior beats Summit Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Indivior compare to Regencell Bioscience?

Indivior (NASDAQ:INDV) and Regencell Bioscience (NASDAQ:RGC) are both mid-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

Indivior has a net margin of 19.44% compared to Regencell Bioscience's net margin of 0.00%. Regencell Bioscience's return on equity of 0.00% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	19.44%	-219.26%	29.40%
Regencell Bioscience	N/A	N/A	N/A

Indivior has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.70	$210M	$1.95	19.29
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

60.3% of Indivior shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. 0.7% of Indivior shares are held by company insiders. Comparatively, 2.0% of Regencell Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Indivior currently has a consensus target price of $39.33, suggesting a potential upside of 4.55%. Given Indivior's stronger consensus rating and higher possible upside, equities analysts plainly believe Indivior is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Indivior has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market.

In the previous week, Regencell Bioscience had 17 more articles in the media than Indivior. MarketBeat recorded 17 mentions for Regencell Bioscience and 0 mentions for Indivior. Indivior's average media sentiment score of 0.53 beat Regencell Bioscience's score of 0.01 indicating that Indivior is being referred to more favorably in the media.

Company	Overall Sentiment
Indivior	Positive
Regencell Bioscience	Neutral

Summary

Indivior beats Regencell Bioscience on 10 of the 14 factors compared between the two stocks.

Get Indivior News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INDV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INDV vs. The Competition

Export

Metric	Indivior	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.59B	$2.96B	$6.68B	$11.99B
Dividend Yield	N/A	1.70%	2.67%	5.55%
P/E Ratio	19.29	18.12	24.06	23.63
Price / Sales	3.70	286.06	519.33	112.45
Price / Cash	13.83	56.84	42.23	54.60
Price / Book	-48.23	3.83	9.73	6.35
Net Income	$210M	$75.85M	$3.57B	$337.59M
7 Day Performance	4.44%	-1.85%	-1.28%	-2.52%
1 Month Performance	-5.00%	-5.62%	1.38%	-0.03%
1 Year Performance	167.38%	14.98%	23.93%	25.34%

Indivior Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INDV Indivior	1.8887 of 5 stars	$37.62 +0.5%	$39.33 +4.6%	+167.4%	$4.59B	$1.24B	19.29	1,051
GMAB Genmab A/S	4.1978 of 5 stars	$26.87 flat	$39.07 +45.4%	+13.3%	$16.75B	$3.72B	20.36	3,029
ASND Ascendis Pharma A/S	4.6445 of 5 stars	$247.05 flat	$295.39 +19.6%	+21.6%	$15.41B	$814.57M	28.49	1,189	News Coverage Positive News Short Interest Decrease
BBIO BridgeBio Pharma	3.5468 of 5 stars	$69.12 flat	$88.90 +28.6%	+75.1%	$13.54B	$502.08M	N/A	400	Analyst Forecast
SMMT Summit Therapeutics	3.2939 of 5 stars	$16.62 flat	$26.05 +56.8%	-28.3%	$12.90B	N/A	N/A	110	News Coverage Insider Trade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INDV) was last updated on 6/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Indivior (INDV) Competitors

INDV vs. GMAB, ASND, BBIO, SMMT, and RGC

How does Indivior compare to Genmab A/S?

Summary

How does Indivior compare to Ascendis Pharma A/S?

Summary

How does Indivior compare to BridgeBio Pharma?

Summary

How does Indivior compare to Summit Therapeutics?

Summary

How does Indivior compare to Regencell Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDV vs. The Competition

Indivior Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Indivior (INDV) Competitors

INDV vs. GMAB, ASND, BBIO, SMMT, and RGC

How does Indivior compare to Genmab A/S?

Does the media refer more to GMAB or INDV?

Is GMAB or INDV more profitable?

Do insiders & institutionals hold more shares of GMAB or INDV?

Which has more risk & volatility, GMAB or INDV?

Do analysts rate GMAB or INDV?

Which has preferable earnings and valuation, GMAB or INDV?

Summary

How does Indivior compare to Ascendis Pharma A/S?

Is INDV or ASND more profitable?

Do analysts rate INDV or ASND?

Do insiders and institutionals have more ownership in INDV or ASND?

Which has higher valuation and earnings, INDV or ASND?

Which has more risk and volatility, INDV or ASND?

Does the media favor INDV or ASND?

Summary

How does Indivior compare to BridgeBio Pharma?

Do insiders & institutionals have more ownership in INDV or BBIO?

Which has higher valuation and earnings, INDV or BBIO?

Does the media prefer INDV or BBIO?

Which has more volatility and risk, INDV or BBIO?

Is INDV or BBIO more profitable?

Do analysts rate INDV or BBIO?

Summary

How does Indivior compare to Summit Therapeutics?

Do analysts prefer SMMT or INDV?

Do insiders and institutionals have more ownership in SMMT or INDV?

Which has better earnings & valuation, SMMT or INDV?

Which has more risk & volatility, SMMT or INDV?

Does the media favor SMMT or INDV?

Is SMMT or INDV more profitable?

Summary

How does Indivior compare to Regencell Bioscience?

Is INDV or RGC more profitable?

Which has higher earnings & valuation, INDV or RGC?

Do institutionals & insiders hold more shares of INDV or RGC?

Do analysts rate INDV or RGC?

Which has more risk & volatility, INDV or RGC?

Does the media prefer INDV or RGC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDV vs. The Competition

Indivior Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools